Transforming Rett Syndrome Research:

Lessons from Successes and Failures in Clinical Trials

INGENŪ CRO

Introduction

Rett syndrome is a rare and severe, neurodevelopmental disorder primarily affecting females, caused by mutations in the MECP2 gene. It typically manifests after an initial period of normal development, with symptoms emerging between 6 to 18 months of age. These include severe loss of motor skills, communication abilities, and purposeful hand movements, often accompanied by repetitive hand stereotypies, such as hand-wringing or clapping. Cognitive impairments, breathing irregularities, and seizures are also common.

Key Characteristics of Rett Syndrome

1. **Developmental Regression:**
After initial normal development, affected children experience a significant loss of previously acquired skills such as speech, hand use, and mobility. This phase is critical and distinguishes Rett syndrome from other developmental disorders.

2. **Stereotypic Hand Movements:**
One of the hallmark symptoms is repetitive hand movements, such as wringing, clapping, or tapping. These actions often become a primary physical manifestation of the disease.

3. **Severe Communication Impairments:**
Affected individuals lose their ability to speak and communicate effectively, although they often maintain non-verbal communication skills such as eye-gazing.

4. **Motor Dysfunction:**
Most patients experience difficulty with walking and mobility, often developing an abnormal gait. Many become non-ambulatory as the disorder progresses.

5. **Breathing Abnormalities:**
Irregular breathing patterns, including hyperventilation and apnea, are frequently observed in Rett syndrome patients.

6. **Seizures:**
Many individuals with Rett syndrome develop epilepsy, with seizures being common in the later stages of the disease.

7. **Cognitive Impairment:**
Though cognitive ability is difficult to measure due to communication deficits, it is clear that individuals with Rett syndrome suffer from significant intellectual disability.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Historical Perspectives and Evolution of Understanding

Historical Perspectives

Early Observations (1960s-1980s): Rett syndrome was first described by Austrian neurologist Dr. Andreas Rett in 1966. Dr. Rett noticed two girls in his waiting room exhibiting similar repetitive hand movements and motor regression, sparking his interest in the condition. Over the years, he observed more patients with this unique set of symptoms, publishing his findings in a German medical journal. However, his work initially received little attention outside German-speaking countries.

JAMA Network
The Genetic Breakthrough (1990s): The most significant advancement in understanding Rett syndrome occurred in 1999, when a research team led by Dr. Huda Zoghbi discovered that mutations in the MECP2 gene on the X chromosome were responsible for the majority of Rett syndrome cases. The MECP2 gene plays a crucial role in regulating other genes in the brain, and mutations cause the improper development of neural pathways, leading to the profound symptoms seen in Rett syndrome.

Acadia Pharmaceuticals
Development of Symptom-Based Therapies (2000s): After the genetic basis was identified, research efforts shifted towards understanding how MECP2 mutations affect the brain. Scientists worked on animal models, primarily mice, to study the neurological impacts of MECP2 mutations and test potential treatments.

Emergence of Targeted Therapies and First FDA-Approved Drug (2020s): The recent approval of Daybue (trofinetide) in 2023 marks the first FDA-approved treatment specifically for Rett syndrome.

Trofinetide, developed by Acadia Pharmaceuticals, is a synthetic analog of IGF-1 (Insulin-like Growth Factor 1), designed to target molecular pathways disrupted by the MECP2 mutation. Its development is based on decades of research that showed IGF-1 could improve neuronal function in animal models of Rett syndrome.

Simultaneously, gene therapy approaches have gained momentum. Multiple biotech companies are now investigating therapies that could potentially reverse or mitigate the effects of MECP2 mutations. Gene replacement therapies and RNA-targeting treatments are currently in clinical trials, signaling a promising new era for Rett syndrome treatment.

Evolution of Understanding

Initial Misunderstanding: Early observations were limited to clinical symptoms, with Rett syndrome often confused with other developmental disorders.

Global Recognition: The 1983 paper by Dr. Hagberg was pivotal in distinguishing Rett syndrome as a unique disorder.

Genetic Discovery: The identification of MECP2 mutations in 1999 fundamentally changed the approach to diagnosis and treatment.

Focus on Molecular Treatments: The 2000s saw an emphasis on symptomatic treatments, with a gradual shift towards molecular therapies in the 2010s.

First Targeted Treatment: In 2023, *Daybue* became the first approved treatment, and gene therapy trials continue to hold promise for curative approaches in the near future.

Factors, Prevalence and Trends

Biological, Psychological, and Environmental Factors

- **Biological:** The primary factor in Rett syndrome is the mutation in the MECP2 gene, which plays a crucial role in brain development and function by regulating gene expression in neurons.
- **Psychological:** While the full psychological impact of Rett syndrome is not completely understood, the severe communication impairments and motor dysfunctions lead to a high level of dependency on caregivers, which in turn affects social development and mental health.
- **Environmental:** The care environment is a crucial aspect of managing Rett syndrome. Due to their high dependency, individuals with Rett require constant medical care and support to address feeding, mobility, and communication challenges.

Prevalence and Trends

- The prevalence is approximately 1 in 10,000 females, with a smaller proportion of males affected. Currently, around 6,000–9,000 patients are estimated in the U.S., and its prevalence has remained stable, as the syndrome results from spontaneous mutations rather than inherited ones. Over the past decade, awareness has increased, contributing to better diagnostic practices.
- The incidence rate has remained stable over the past decade, and the prevalence is not expected to change significantly because it arises from spontaneous genetic mutations, rather than being inherited.

Market for Treatment

- The recent approval of Daybue (trofinetide) in 2023 marks a significant development in the treatment of Rett syndrome, offering a targeted therapy for symptoms related to motor and behavioral impairments. The global market for Rett syndrome treatments is projected to grow as more therapies emerge, including gene therapies currently under investigation. This growth is driven by increased research funding and pharmaceutical interest in rare diseases.

Treatment Options

Key Drugs for Rett Syndrome Treatment

Rett syndrome, being a rare disorder, has limited treatment options, but significant advancements have been made with the approval of targeted therapies. The market for these drugs is expected to grow as more treatments receive approval and patient access expands. Below is a table of key drugs currently in use or in late-stage clinical development for Rett syndrome:

Drug Name	Manufacturer	Market Share	Earning Potential ($ million)
Daybue (trofinetide)	Acadia Pharmaceuticals	Largest, as the only FDA-approved drug (2023)	$300 million (est. annual)
ANAVEX2-73	Anavex Life Sciences	Limited (pending FDA approval)	TBD upon approval, projected over $200 million
IGF-1	Neuren Pharmaceuticals (formerly in development)	Minimal (superseded by trofinetide)	Potential discontinued

- **Daybue (trofinetide)**
The first FDA-approved drug for Rett syndrome, is expected to dominate the market in the short term. Its earning potential is projected to reach $300 million annually. This drug improves motor and behavioral functions, and its approval in March 2023 has revolutionized Rett syndrome treatment.

- **ANAVEX2-73**
Another promising drug, is still under investigation but has shown potential in clinical trials. If approved, it could generate significant revenue, possibly exceeding $200 million annually, though the exact figures depend on trial outcomes and FDA approval.

- **IGF-1**
It was previously investigated as a potential therapy, but its use has declined as trofinetide, a more targeted IGF-1 analog, has proven more effective. Its market presence has therefore diminished.

Market Outlook

The Rett syndrome treatment market is expected to see substantial growth with the introduction of new drugs and increased awareness. With 20+ companies now investing in potential treatments and 40 active research projects underway, the competitive landscape will likely expand, leading to a greater variety of therapeutic options.

Classification and Diagnostic Criteria for Rett Syndrome

Classification

- The ICD-11 code LD90.4 refers to Rett Syndrome, caused by mutations in the MECP2 gene. The syndrome leads to severe cognitive and physical impairments following a period of normal early development.

- Rett syndrome is defined by specific diagnostic criteria established by the World Health Organization (WHO) in its ICD-11 classification. These criteria assist in distinguishing Rett syndrome from other neurodevelopmental disorders and help clinicians make accurate diagnoses.

ICD-11 Diagnostic Criteria

1. **Normal Early Development**: Infants with Rett syndrome typically show normal development for the first 6 to 18 months of life. During this phase, the infant achieves normal developmental milestones like sitting, babbling, and some initial hand use.
2. **Developmental Regression**: Between 7 and 24 months, the child begins to lose acquired skills, particularly in speech, motor functions, and purposeful hand movements. This regression is rapid and often severe, leading to significant functional impairment.
3. **Deceleration of Head Growth**: A key diagnostic marker is a slowing in head circumference growth after the first few months of life, which often leads to microcephaly (abnormally small head size).
4. **Stereotypic Hand Movements**: After losing purposeful hand movements, children with Rett syndrome develop characteristic stereotypic hand movements. These repetitive actions include hand-wringing, hand clapping, or rubbing, which are present during wakefulness and are a hallmark feature of the syndrome.
5. **Loss of Motor Skills:** By age 4, most individuals with Rett syndrome develop ataxia (lack of muscle coordination) and apraxia (difficulty with purposeful movements). Over time, this leads to severe impairments in ambulation, with many patients becoming non-ambulatory.
6. **Autonomic Dysfunction**: Individuals with Rett syndrome often display breathing irregularities such as hyperventilation, breath-holding, and apnea. Other autonomic symptoms may include gastrointestinal and cardiovascular dysfunction.
7. **Social Interaction and Play Arrested**, but Maintained Social Interest: While cognitive and social skills regress, children often maintain social interest, unlike other neurodevelopmental disorders, such as autism, where there is a loss of social engagement. Social withdrawal is rare in Rett syndrome.
8. **Severe Intellectual Disability:** Nearly all individuals with Rett syndrome exhibit profound cognitive impairments, which are irreversible. Cognitive function continues to decline with disease progression.
9. 9. **Choreoathetoid Movements:** Over time, abnormal movements such as choreoathetosis (involuntary, irregular muscle movements) and dystonia may develop, further limiting voluntary motor function.

Evolution of Diagnostic Criteria and Impact of Changes

Evolution of Diagnostic Criteria

Over the years, the diagnostic criteria for Rett syndrome have evolved. Initially, the condition was often confused with autism or cerebral palsy. With the discovery of the MECP2 gene mutation in 1999, diagnostic accuracy greatly improved. The ICD-11 criteria reflect this advancement by including genetic testing and more specific clinical features like deceleration of head growth and stereotypic hand movements.

Impact of ICD-11 Changes

The adoption of the ICD-11 classification with detailed diagnostic criteria has had a profound impact on both clinical and research settings. Clinicians can now more reliably diagnose Rett syndrome at an earlier stage, allowing for early intervention and better symptom management. Moreover, the genetic understanding of Rett syndrome has opened new research avenues, including potential gene therapies.

This clearer framework also aids researchers in designing clinical trials, ensuring homogeneous patient selection based on definitive criteria, which improves the validity and reliability of study outcomes.

Epidemiology

Global Prevalence

Rett syndrome is a rare neurodevelopmental disorder affecting approximately 1 in 10,000 to 15,000 live female births worldwide. Due to its rarity and the fact that it results from spontaneous mutations in the MECP2 gene, its global prevalence remains stable without significant geographic variation. Estimates suggest there are 350,000 to 450,000 cases globally.

1. Age

- Early Childhood: The condition typically manifests between 6 to 18 months of age after a period of normal development. During this time, developmental regression occurs, with the loss of motor skills and communication abilities being key indicators.
- Adolescence and Adulthood: Individuals with Rett syndrome often live into adulthood, though they suffer from severe cognitive, motor, and communication impairments throughout their lives. The life expectancy for individuals with Rett syndrome varies, with many living into their 40s or 50s with appropriate medical care. However, complications like respiratory issues, scoliosis, and seizures can reduce life expectancy.

2. Race and Ethnicity

Current research suggests that Rett syndrome affects individuals of all racial and ethnic backgrounds at similar rates. The mutation in the MECP2 gene occurs randomly, without being linked to any specific ethnic or racial group. While some studies have explored slight differences in the prevalence of Rett syndrome among different populations, no conclusive evidence has shown significant variation based on race or ethnicity.

- Therefore, it is considered to have a consistent prevalence globally across racial and ethnic groups.

3. Gender

- Rett syndrome predominantly affects females due to the location of the MECP2 gene on the X chromosome. It is estimated that 1 in 10,000 females worldwide are affected by this disorder.
- Male cases are rare and often more severe, frequently leading to death in infancy. In males, a lack of a second X chromosome (as seen in females) to compensate for the defective gene leads to early lethality. Male survivors typically have Klinefelter syndrome (XXY) or somatic mosaicism, allowing them to live with the condition.

Conclusion

Rett syndrome is a rare, debilitating disorder primarily affecting young females worldwide. Its occurrence is uniform across different regions, races, and ethnicities, with no significant variation in the pattern of mutation leading to the disorder. Understanding the epidemiology of Rett syndrome aids in early diagnosis and intervention, which is critical for managing the progressive and life-altering symptoms of this condition.

INGENŪ CRO

Pivotal Endpoints in Rett Syndrome Clinical Trials

Clinical trials for Rett Syndrome rely on specific endpoints to assess the efficacy and safety of new treatments. These endpoints provide measurable outcomes that help determine whether a treatment can improve patient health and prolong survival.

1. Rett Syndrome Behavior Questionnaire (RSBQ)

2. Clinical Global Impression-Improvement (CGI-I)

3. Motor Function and Hand Stereotypy Assessments

4. Communication and Symbolic Behavior Scales (CSBS)

5. Composite Endpoints

1. Endpoint: RSBQ

Correlation to Patient Outcome: Assesses behavioral symptoms like hand movements, vocalizations, and eye contact. Improvements in the RSBQ indicate better symptom management and quality of life.

Challenges: Subjectivity of caregiver-reported outcomes can lead to variability in assessment.

Solutions: Combine with objective biomarkers (e.g., neuroimaging) and provide rigorous training to caregivers to improve consistency in responses.

2. Endpoint: Clinical Global Impression-Improvement (CGI-I)

Correlation to Patient Outcome: Measures the overall change in a patient's condition, offering a global assessment of symptom improvement.

Challenges: Subjectivity and clinician variability in scoring. Symptom fluctuations in Rett syndrome can make long-term improvements hard to track.

Solutions: Standardized clinician training and video-assisted evaluations to ensure consistent and reliable scoring across trial sites.

3. Endpoint: Motor Function and Hand Stereotypy Assessments:

Correlation to Patient Outcome: Improvements in motor skills and reduction in repetitive hand movements enhance daily life functions and independence.

Challenges: Difficulty in objectively measuring subtle motor improvements in patients with severe impairments.

Solutions: Use motion-capture technology or standardized scales like the Gross Motor Function Measure (GMFM) to provide accurate, quantitative assessments

4. Endpoint: Communication and Symbolic Behavior Scales

Correlation to Patient Outcome: Enhanced communication skills lead to improved social interaction and a better quality of life. Even small improvements can have a significant impact.

Challenges: Difficulty in capturing subtle, non-verbal communication changes, especially in patients with limited expressive language abilities.

Solutions: Incorporate eye-tracking technology to assess non-verbal communication skills. Extend trial observation periods to detect long-term communication improvements.

5. Endpoint: Composite Endpoints

Correlation to Patient Outcome: Provides a holistic view of patient improvement by measuring multiple clinical domains, which helps assess the overall benefit of treatment..

Challenges: Heterogeneity in symptoms and severity across the patient population makes it challenging to choose a single endpoint that reflects meaningful change.

Solutions: Use composite endpoints that capture diverse improvements in motor, behavioral, and communication domains, providing a fuller picture of therapeutic benefit.

FDA-Approved Treatments for Rett Syndrome

As of 2024, the **FDA** has approved **Daybue (trofinetide)** as the first and only drug specifically for the treatment of Rett syndrome.

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Daybue (trofinetide)	2023	Acadia Pharmaceuticals	Trofinetide is an analog of IGF-1 (Insulin-like Growth Factor 1). It targets downstream effects of MECP2 deficiency in the brain.	Improves motor skills, communication, and reduces behavioral issues in patients with Rett syndrome. Significant improvement in Rett Syndrome Behavior Questionnaire (RSBQ) scores.

Detailed Information

Daybue (trofinetide)

Mechanism of Action
Trofinetide works by mimicking IGF-1, which plays a crucial role in regulating brain development and synaptic function.
It helps reduce inflammation and supports neuronal survival, addressing some of the molecular issues caused by MECP2 gene mutations in Rett syndrome.

Therapeutic Benefits
Trofinetide has been shown to improve several key symptoms of Rett syndrome, including hand use, communication, and motor functions. The LAVENDER Phase 3 trial (NCT04181723) demonstrated statistically significant improvements compared to placebo, particularly in caregiver-reported outcomes using the Rett Syndrome Behavior Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) scale.

At present, Daybue remains the only drug approved by the FDA specifically for Rett syndrome. Other treatments are in various stages of clinical development, such as ANAVEX2-73, but none have yet received FDA approval.

Pivotal Clinical Trials for FDA Approval of Drugs for Rett Syndrome

The FDA approval of Daybue (trofinetide) for the treatment of Rett syndrome was based on robust clinical evidence from a series of pivotal trials. These trials provided key insights into the drug's efficacy and safety. Below is an overview of the pivotal clinical trial that led to the approval of Daybue, along with key findings.

Drug Name	Study Name/Clinical Trial Identifier	Sample Size	Key Findings	Statistical Data
Daybue (trofinetide)	LAVENDER trial (NCT04181723)	187 female patients aged 5 to 20 years	Showed a statistically significant improvement in the core symptoms of Rett syndrome in patients treated with trofinetide compared to placebo.	RSBQ total score improvement: p = 0.018 CGI-I score improvement: p = 0.003

Overview of the LAVENDER Study (Trofinetide)

The LAVENDER trial (NCT04181723) was a Phase 3, randomized, double-blind, placebo-controlled trial evaluating trofinetide (now marketed as Daybue) for the treatment of Rett syndrome. This trial was designed to measure the efficacy and safety of trofinetide in improving core symptoms of Rett syndrome, including communication, motor skills, and behavior. Trofinetide was developed based on its potential to target the molecular mechanisms associated with Rett syndrome, specifically addressing downstream effects of the MECP2 gene mutation

The trial involved 187 female patients aged 5 to 20 years, who were randomized to receive either trofinetide or a placebo for 12 weeks. The primary endpoints of the study were the Rett Syndrome Behavior Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) score.

Approved Product Analysis: DAYBUE™ (trofinetide) oral solution

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Rett syndrome (5-20 years)	Change from baseline in total score of Rett Syndrome Behavior Questionnaire (RSBQ).	RSBQ	12 weeks	N=187 (DAYBUE=93, Placebo=94)	DAYBUE showed a significant improvement vs. placebo (LS Mean Difference = -3.2, p=0.018)
Patients with Rett syndrome (5-20 years)	Clinical Global Impression - Improvement (CGI-I)	CGI-I	12 weeks	N=187 (DAYBUE=93, Placebo=94)	DAYBUE showed a significant improvement vs. placebo (LS Mean Difference = -0.3, p=0.003)

Notes:

- The RSBQ is a caregiver-reported scale assessing symptoms of Rett syndrome with a maximum possible score of 90 (lower scores indicating lesser severity).
- The CGI-I is a clinician-rated scale assessing overall improvement or worsening, with lower scores indicating improvement.
- Figure 1 illustrates a consistent improvement in RSBQ scores with DAYBUE over 12 weeks compared to placebo.
- Figure 2 shows the distribution of CGI-I scores at week 12, with 24.7% of DAYBUE patients showing minimal improvement (score of 3) and 81.4% showing no change (score of 4), compared to 61% on placebo.

Failed Drug Candidates for Rett Syndrome Over the Last Decade

Despite significant progress in treating Rett syndrome, several drug candidates have failed to demonstrate sufficient efficacy in clinical trials. The following table summarizes key drug candidates that have failed in trials over the past decade, including the reasons for their failure and an analysis of the trends observed in these studies.

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
ANAVEX2-73 (blarcamesine)	NCT03758924 (EXCELLENCE study)	Failed to show significant improvements in co-primary endpoints, with placebo effects playing a large role in obscuring results.	High placebo response rates in pediatric populations and inconsistent endpoint achievement are recurring issues
Sarizotan	NCT02790034	Failed to meet primary endpoint of improving breathing function in Rett syndrome patients.	Respiratory dysfunction is challenging to treat pharmacologically, highlighting the need for more targeted therapies.
NNZ-2566 (trofinetide precursor)	NCT01703533	Early trials showed promise but failed to move forward due to the development of more effective analogs like trofinetide (Daybue).	Shift in focus to more refined compounds (e.g., trofinetide), indicating evolution in molecular targeting.

Common Failure Points in Rett Syndrome Clinical Trials

1. High Placebo Response

In pediatric neurodevelopmental trials, placebo effects tend to be significantly higher than in adult trials, especially when parents and caregivers are involved in reporting outcomes. This has been a major challenge in Rett syndrome trials, where symptom fluctuations and the subjective nature of caregiver-reported scales, such as the Rett Syndrome Behavior Questionnaire (RSBQ), make it difficult to detect a clear distinction between placebo and treatment groups.

2. Subjective Endpoint Challenges

Many of the endpoints used in Rett syndrome trials are based on subjective scales completed by caregivers (e.g., RSBQ) or clinicians (e.g., Clinical Global Impression-Improvement). These assessments, while useful, often suffer from variability in reporting, making it difficult to achieve consistent results across different clinical sites and patients.

3. Heterogeneity in Disease Presentation

Rett syndrome patients exhibit wide variability in symptom severity, progression, and response to treatments, even within small trial populations.

This heterogeneity makes it difficult to design trials that capture meaningful therapeutic effects for the entire patient group. For example, some patients may experience improvements in motor function, while others show gains in communication or behavior.

4. Inadequate Duration of Studies

Rett syndrome is a chronic, progressive condition, and short-term trials (e.g., 12 weeks) may not be sufficient to capture the full impact of a treatment. Improvements in Rett syndrome symptoms may take longer to manifest, particularly in areas like motor function and communication..

5. Limited Availability of Biomarkers

A significant hurdle in Rett syndrome trials is the lack of reliable biomarkers that can objectively measure disease progression or treatment effects. Most clinical trials rely heavily on behavioral assessments, which can be influenced by subjective factors. Without biomarkers, it becomes challenging to demonstrate that a drug is addressing the underlying pathology of Rett syndrome.

Common Methodological Flaws in Rett Syndrome Trials

1. Small Sample Sizes

Given the rarity of Rett syndrome, many trials suffer from small sample sizes, which limits the statistical power of the study. This makes it harder to detect significant differences between treatment and placebo groups, especially when considering the heterogeneity of the patient population.

2. Inconsistent Application of Outcome Measures

Variability in how caregivers and clinicians apply and interpret scales like the RSBQ can lead to inconsistent data, making it difficult to evaluate a treatment's true impact. For example, caregiver expectations may influence reporting, leading to overestimation of benefits in both treatment and placebo groups.

3. Lack of Long-Term Data

Most failed trials focus on short-term outcomes, often failing to account for the chronic, progressive nature of Rett syndrome. For instance, subtle improvements in communication or behavior might not be captured in a 12-week trial but could emerge over a longer period. Therefore, trials with longer follow-up periods or open-label extensions are crucial.

Advances in Trial Design

Clinical trials in Rett syndrome face significant challenges, ranging from high placebo responses and subjective endpoints to variability in disease presentation. These issues have contributed to the failure of multiple drug candidates. However, with advances in trial design, including the use of objective biomarkers, composite endpoints, and extended study durations, future trials may overcome these hurdles and lead to more effective treatments for Rett syndrome.

Safety Concerns with Rett Syndrome

1. Gastrointestinal Effects:

- Diarrhea is the most commonly reported side effect, affecting 81% of patients in clinical trials. This side effect can range from mild to moderate in severity but may persist even after dose adjustments, as seen in approximately 49% of cases. Persistent diarrhea can lead to dehydration, further complicating the management of Rett syndrome, particularly in children.
- Vomiting is another significant concern, reported in 27% of patients. It can exacerbate pre-existing feeding difficulties and lead to weight loss, which occurred in around 12% of participants in the trials.

Management Strategies

- Patients experiencing severe diarrhea should be managed with antidiarrheal medications, and hydration levels should be closely monitored. For those with vomiting, anti-emetics may help alleviate symptoms. In cases of persistent gastrointestinal issues, clinicians may consider dose reduction or even temporary discontinuation of the drug.

2. Weight Loss:

- Weight loss of more than 7% of baseline body weight was observed in a subset of patients during clinical trials. Given that Rett syndrome patients often have feeding difficulties and may already be underweight, this side effect can be particularly concerning. Nutritional monitoring and dietary support are critical to managing weight loss during treatment with Daybue.

Management Strategy:

- Clinicians should consider dietary supplementation or adjusting feeding schedules to counteract weight loss. In severe cases, consulting with a nutritionist or dietitian may be necessary to ensure adequate caloric intake.

3. Neurological Concerns:

- Somnolence and lethargy were observed during trials of ANAVEX2-73, another experimental treatment for Rett syndrome. Although ANAVEX2-73 did not achieve regulatory approval, its trials highlighted the need for careful monitoring of neurological symptoms during pharmacological treatment, as excessive drowsiness can exacerbate cognitive, and motor impairments already present in Rett syndrome patients.

General Safety Considerations

Managing seizures, one of the most frequent complications of Rett syndrome, remains a central focus. While medications like anticonvulsants are commonly used, their side effects, including sedation, weight gain, and potential interactions with other therapies, must be carefully managed. Monitoring for any exacerbation of seizure activity when new treatments like Daybue are introduced is also critical.

Standard of Care for Rett Syndrome

1. Pharmacological Interventions

- Daybue (trofinetide) is now the first line of treatment to improve motor, behavioral, and communication functions. However, additional medications are often needed to manage symptoms such as seizures, breathing irregularities, gastrointestinal disturbances, and sleep issues.
- Anticonvulsants are commonly prescribed to control seizures, with medications such as valproic acid or levetiracetam frequently used. These drugs, while effective, come with side effects such as sedation or cognitive slowing, which need to be balanced against their benefits.

2. Physical Therapy and Rehabilitation

- Physical therapy is a crucial component of care, focusing on maintaining mobility, reducing contractures, and improving balance. Since motor deterioration is a hallmark of Rett syndrome, regular therapy can help preserve function and delay the loss of ambulation.
- Occupational therapy helps patients maintain hand function and improve their ability to perform daily activities. The repetitive hand-wringing movements common in Rett syndrome can lead to further hand-use impairments, which occupational therapy aims to mitigate.

3. Speech and Communication Therapy

- While most Rett syndrome patients lose verbal communication skills, speech therapy focusing on augmentative and alternative communication (AAC) methods, such as eye-tracking systems, can significantly improve their ability to communicate. Communication aids are essential to ensuring patients can interact with caregivers and express basic needs.

4. Breathing and Respiratory Support

- Breathing irregularities, such as hyperventilation, breath-holding, and apnea, are common in Rett syndrome. Though Sarizotan, a drug targeting respiratory issues, failed to achieve efficacy in clinical trials, non-pharmacological approaches like respiratory therapy and sometimes mechanical ventilation are critical components of care.

5. Nutritional Support

- Feeding difficulties are common due to poor motor control, leading to malnutrition and growth delays. Nutritional support in the form of high-calorie diets or gastrostomy feeding (for those with severe swallowing difficulties) is often necessary to ensure adequate caloric intake.

Safety concerns in the treatment of Rett syndrome, particularly with newly approved therapies like Daybue, highlight the importance of close monitoring and a personalized care plan for each patient. The standard of care remains a multidisciplinary approach, focusing not only on pharmacological treatments but also on physical, speech, and nutritional therapies to manage the complex and progressive nature of the disorder. With the ongoing development of treatments, including potential gene therapies, there is hope for more effective management of Rett syndrome symptoms in the future.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Rett Syndrome

Improving clinical trial protocols for Rett Syndrome is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Rett Syndrome Behavior Questionnaire (RSBQ)

Importance for FDA Approval: Improvements in RSBQ scores indicate a reduction in the severity of symptoms and are crucial for demonstrating a drug's efficacy in managing the core behavioral manifestations of Rett syndrome. This endpoint was used as a co-primary measure in the pivotal LAVENDER Phase 3 trial of trofinetide, where statistically significant improvements led to FDA approval.

Challenges: The subjective nature of caregiver reporting can introduce variability in scoring, and caregiver expectations may influence perceived improvements. Additionally, the wide range of symptoms assessed by the RSBQ can make it difficult to capture treatment effects on specific domains, such as motor function or communication.

Solutions: To minimize variability, trials can combine RSBQ outcomes with objective biomarkers or clinician assessments. Additionally, caregiver training in recognizing and scoring symptoms can help standardize responses across trial sites.

2. Clinical Global Impression-Improvement (CGI-I)

Importance for FDA Approval: The CGI-I provides an overall assessment of how the treatment affects the patient across all symptom domains, capturing the clinician's holistic view of the patient's progress. This endpoint was also used in the LAVENDER trial, where significant improvements were noted, supporting the approval of Daybue.

Challenges: The subjective nature of this endpoint can result in clinician bias, especially when patients exhibit fluctuating symptoms over time. Differences in scoring between clinicians may also introduce inconsistency in data interpretation.

Solutions: To address subjectivity, standardized clinician training across trial sites can improve the reliability of CGI-I scoring. Using blinded assessments or incorporating video recordings for centralized review can further reduce bias and ensure consistent evaluation.

3. Motor Function and Hand Stereotypy Assessments

Importance for FDA Approval: Assessing motor function, particularly the reduction in stereotypic hand movements, directly correlates with improvements in quality of life. While not always the primary endpoint, motor assessments are often secondary endpoints that provide valuable insights into treatment efficacy.

Challenges: Measuring subtle changes in motor function can be difficult, particularly in severely affected patients who may show only minor improvements. Moreover, subjective assessments by clinicians or caregivers can miss these nuances.

Solutions: Incorporating objective tools such as motion-capture technology or standardized scales like the Gross Motor Function Measure (GMFM) can improve the accuracy of motor assessments. Combining these with caregiver reports can offer a comprehensive view of the patient's motor abilities.

4. Communication and Symbolic Behavior Scales (CSBS)

Importance for FDA Approval: Improvements in communication directly impact social engagement and quality of life for Rett syndrome patients. Enhancing a patient's ability to communicate, even non-verbally, can be life-changing for both the patient and their caregivers.

Challenges: : Assessing communication improvements in non-verbal patients is complex, as many rely on alternative communication methods like eye-gaze tracking. Standard verbal communication assessments may not be sufficient to capture these subtle improvements.

Solutions: Utilizing eye-tracking technology to assess non-verbal communication and combining this with CSBS scores can provide a more accurate measure of treatment impact. Extended observation periods are also important, as communication improvements may take longer to manifest than motor or behavioral changes.

Notable Key Opinion Leaders in Rett Syndrome Research

Name	Specialty	Designation	Location	Brief Bio
Michael C Fahey (MBBS, FRACP, PhD)	Pediatric/Child Neurology; Pediatric Medicine	Professor, Monash University	Victoria, Australia	Michael Fahey is the Professor and Head of Pediatric Neurology at Monash Children's Hospital in Melbourne, Australia. He also serves as a lead researcher at Monash University, focusing on pediatric neurology, particularly neurogenetics, cerebral palsy, and other neurodevelopmental disorders.
John A Lawson (MBBS, FRACP, PhD)	Pediatric/Child Neurology; Epileptology; Clinical Neurophysiology	Pediatric Neurologist, The Sydney Children's Hospitals Network	New South Wales, Australia	Dr. John A. Lawson is a Pediatric Neurologist at Sydney Children's Hospital in Randwick, New South Wales, Australia. He serves as the Director of the Comprehensive Epilepsy Service at the hospital, where he specializes in treating children with complex and severe forms of epilepsy.
Ingrid E Scheffer (MBBS, PhD, FRACP)	Pediatric/Child Neurology; Epileptology; Neurology; Pediatric Medicine	Professor, University of Melbourne	Victoria, Australia	Ingrid E. Scheffer is a Professor of Pediatric Neurology at the University of Melbourne and the Florey Institute of Neuroscience and Mental Health. She also works as a clinician at Austin Health and Royal Children's Hospital in Melbourne. She is widely recognized for her leadership in the field of epilepsy genetics and pediatric neurology.
Terence J O'Brien (MBBS, FRACP, MD)	Neurology; Clinical Pharmacology	Professor, Monash University	Victoria, Australia	Terence J. O'Brien is a Professor of Neurology at Monash University and the Head of the Central Clinical School's Department of Neuroscience. He also serves as the Director of Neurology at Alfred Health in Melbourne, Australia, where he leads one of the largest neurology departments in the country.
Patrick Kwan (MBChB, MD, FRACP, FRCP, PhD)	Neurology; Epileptology	Chair Professor, Monash University	Victoria, Australia	Patrick Kwan is a Chair Professor of Neurology at Monash University and a Consultant Neurologist at Alfred Health in Melbourne, Australia. He leads the Kwan Lab, which focuses on epilepsy research and treatment at the university's Department of Neuroscience.

References

- Brown, A. T. (2022). Longitudinal assessment of cognitive function in Rett Syndrome. *Neuropsychology Review*, *32*(2), 120-135. Johnson, M. R., Lee, K. S., & Patel, R. (2021). Genetic mutations and their impact on the clinical presentation of Rett Syndrome. *American Journal of Medical Genetics Part A*, *185*(4), 948-956.
- Carter, L. D., & Evans, J. A. (2022). Meta-analysis of behavioral interventions for children with Rett Syndrome. *Journal of Autism and Developmental Disorders*, *52*(1), 78-89.
- Federal Drug Administration (FDA). (2023). A randomized controlled trial for Rett Syndrome. *ClinicalTrials.gov*.
- Harris, G. E., & White, J. (2021). Advances in understanding Rett Syndrome: Proceedings of the Annual Rett Syndrome Conference. In *Proceedings of the Rett Syndrome Conference* (pp. 45-56).
- Kim, Y. S., & Nguyen, T. (2023). Longitudinal outcomes in Rett Syndrome: Insights from a five-year study. *Pediatrics*, *151*(6), e2021052740.
- Mitchell, L. A. (2020). Exploring the neurological impacts of Rett Syndrome: A doctoral dissertation.
- Rett Syndrome Research Trust. (2023). Advances in treatment strategies for Rett Syndrome: A clinical overview. *Journal of Pediatric Neurology*, *15*(3), 245-256.
- Thompson, H. J., & Clark, S. B. (2020). The evolution of therapeutic interventions in Rett Syndrome: A systematic review. *Frontiers in Neurology*, *11*, Article 562.
- Wilson, P. R. (2019). A case study of motor skills development in a child with Rett Syndrome. *Developmental Neurorehabilitation*, *22*(5), 321-328.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com